Today: 21 May 2026

UOB share price ticks up in Singapore as traders size up Feb 24 earnings after DBS flags rate headwinds

UOB share price ticks up in Singapore as traders size up Feb 24 earnings after DBS flags rate headwinds

UOB shares rose 0.47% to S$38.88 in afternoon trading Tuesday ahead of its Feb. 24 results. DBS shares fell after reporting a 10% drop in Q4 profit and warning of a volatile 2026. Singapore raised its 2026 GDP forecast to 2–4% following 6.9% Q4 growth, while the central bank said inflation is tracking forecasts. Investors are watching UOB’s net interest margin, fee income, and credit costs.
10 February 2026
··
Keppel share price jumps again as brokers eye S$14 targets — what’s driving BN4 today

Keppel share price jumps again as brokers eye S$14 targets — what’s driving BN4 today

Keppel Ltd shares rose 2.6% to S$12.42 in afternoon trade Tuesday, following last week’s S$1.1 billion net profit and proposed special dividend. Brokers raised target prices toward S$14, citing earnings growth and asset management fees. About 4.09 million shares changed hands as the stock outperformed a flat Straits Times Index. Investors are eyeing the April 17 AGM and April 28 dividend record date.
10 February 2026
·
DBS stock slips in Singapore trade after profit miss; dividend return plan back in focus

DBS stock slips in Singapore trade after profit miss; dividend return plan back in focus

DBS Group shares dropped 0.8% to S$57.75 after fourth-quarter net profit fell 10% to S$2.26 billion, missing estimates. The bank flagged lower net interest margins and raised loan-loss provisions 81% to S$415 million, mainly on real estate. DBS declared a 66-cent final dividend and a 15-cent capital return dividend. Investors await results from OCBC and UOB later this month.
10 February 2026
··
Telstra share price slips as spectrum fee fight heats up ahead of results

Telstra share price slips as spectrum fee fight heats up ahead of results

Telstra shares closed down 0.2% at A$4.87 after the company urged Canberra to cap spectrum licence renewals at A$3.9 billion, challenging regulator guidance of up to A$7.2 billion. The Australian Communications and Media Authority is consulting on pricing, with submissions due Feb. 27. Telstra reports half-year results Feb. 19. The S&P/ASX 200 ended 2.7 points lower at 8,867.40.
10 February 2026
·
1 … 291 292 293 294 295 … 1,961

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop